Integrated Filing — IndAS

General information about company
Scrip Code	532331
NSE Symbol	AJANTPHARM
MSEI Symbol	NA
ISIN	INE031B01049
Name of company	Ajanta Pharma Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	30-Apr-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	PHARMACEUTICAL
Start date and time of board meeting	30-Apr-2025   13:30:00
End date and time of board meeting	30-Apr-2025   15:15:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2022-04-30
Indicate Company website link for updated RPT policy of the Company	https://ajantapharma.com//images/PolicyonRelatedPartyTransactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Nosuchdefault

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	10139400000	43220400000
	Other income	179300000	1198700000
	Total income	10318700000	44419100000
2	Expenses
(a)	Cost of materials consumed	1909600000	8466000000
(b)	Purchases of stock-in-trade	565400000	1840000000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-151000000	-185800000
(d)	Employee benefit expense	2578600000	10109000000
(e)	Finance costs	6700000	46000000
(f)	Depreciation, depletion and amortisation expense	387600000	1399300000
(f)	Other Expenses
1	Other expenses	2740300000	10944000000
	Total other expenses	2740300000	10944000000
	Total expenses	8037200000	32618500000
3	Total profit before exceptional items and tax	2281500000	11800600000
4	Exceptional items	0	0
5	Total profit before tax	2281500000	11800600000
6	Tax expense
7	Current tax	391000000	2580300000
8	Deferred tax	-43800000	51400000
9	Total tax expenses	347200000	2631700000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	1934300000	9168900000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	1934300000	9168900000
17	Other comprehensive income net of taxes	-14300000	-58300000
18	Total Comprehensive Income for the period	1920000000	9110600000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	250700000	250700000
	Face value of equity share capital	2	2
27	Details of debt securities
22	Reserves excluding revaluation reserve		36002400000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	15.46	73.28
	Diluted earnings (loss) per share from continuing operations	15.45	73.25
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	15.46	73.28
	Diluted earnings (loss) per share from continuing and discontinued operations	15.45	73.25
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		1TheabovestandaloneresultshavebeenreviewedbyAuditCommitteeandapprovedbytheBoardofDirectorsattheirmeetingheldon30April2025Thestatutoryauditorshaveexpressedanunmodifiedopinionontheresultsforthequarterandyearended31March2025Thereviewreporthasbeenfiledwiththestockexchangeandisavailableonthecompanyswebsite2Thefiguresforthequarterended31March2025and31March2024arethebalancingfiguresbetweenauditedfiguresinrespectoffullfinancialyearandtheunauditedpublishedyeartodatefiguresuptothethirdquarterended31December2024and31December2023respectively3OtherincomeincludesRsinCroresQuarterendedYearended310325311224310324310325310324Dividendfromsubsidiaries22282913Foreignexchangegain2072182732964316inotherincomeForeignexchangeloss882inotherexpenses4om2May2024companyhasannouncedbuybackofits1028881equitysharesbeing082ofthetotalpaidupequitysharecapitalatRs2770perequityshareforanaggregateamountofRs28500croresThebuybackopenedon05June2024closedon11June2024andCompanyextinguishedthoseshareson27June20245Duringtheyear25325previousyear1000equitysharesofRs2eachfullypaidupwereallotteduponexerciseofvestedoptionspursuanttotheShareBasedIncentivePlan2019resultinginanincreaseinthepaidupsharecapitalbyRs50650previousyearRs2000andsecuritiespremiumbyRs384crorespreviousyearRs018crores

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	16216100000
	Capital work-in-progress	1762700000
	Investment property	0
	Goodwill	0
	Other intangible assets	1203500000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	431300000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	81400000
	Total non-current financial assets	512700000
	Deferred tax assets (net)	0
	Other non-current assets	86900000
	Total non-current assets	19781900000
2	Current assets
	Inventories	7392900000
	Current financial asset
	Current investments	4387100000
	Trade receivables, current	12258100000
	Cash and cash equivalents	486000000
	Bank balance other than cash and cash equivalents	11200000
	Loans, current	25400000
	Other current financial assets	23200000
	Total current financial assets	17191000000
	Current tax assets (net)	0
	Other current assets	1088200000
	Total current assets	25672100000
3	Non-current assets classified as held for sale	88500000
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	45542500000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	250700000
	Other equity	36002400000
	Total equity attributable to owners of parent	36253100000
	Non controlling interest
	Total equity	36253100000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	254400000
	Total non-current financial liabilities	254400000
	Provisions, non-current	802700000
	Deferred tax liabilities (net)	1105100000
	Deferred government grants, Non-current	20000000
	Other non-current liabilities	0
	Total non-current liabilities	2182200000
	Current liabilities
	Current financial liabilities
	Borrowings, current	0
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	215500000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	3447200000
	Total Trade payable	3662700000
	Other current financial liabilities	1656000000
	Total current financial liabilities	5318700000
	Other current liabilities	1385400000
	Provisions, current	233500000
	Current tax liabilities (Net)	166300000
	Deferred government grants, Current	3300000
	Total current liabilities	7107200000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	9289400000
	Total equity and liabilites	45542500000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Re-measurement of defined benefit liability/(assets)	-21900000	-89600000
	Total Amount of items that will not be reclassified to profit and loss	-21900000	-89600000
2	Income tax relating to items that will not be reclassified to profit or loss	-7600000	-31300000
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss
5	Total Other comprehensive income	-14300000	-58300000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			11800600000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			46000000
	Adjustments for decrease (increase) in inventories			-615000000
	Adjustments for decrease (increase) in trade receivables, current			-65900000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			254400000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			-170800000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			1054300000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			1399300000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			6300000
	Adjustments for provisions, current			404900000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-103100000
	Adjustments for dividend income			222800000
	Adjustments for interest income			593300000
	Adjustments for share-based payments			40000000
	Adjustments for fair value losses (gains)			124700000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			-3300000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			1555700000
	Net cash flows from (used in) operations			13356300000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			2818300000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			10538000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			26634800000
	Other cash payments to acquire equity or debt instruments of other entities			27612100000
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			62500000
	Proceeds from sales of property, plant and equipment			8500000
	Purchase of property, plant and equipment			3172000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			222800000
	Interest received			485800000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-1300000
	Net cash flows from (used in) investing activities	-3496000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			100000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			3529500000
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			0
	Payments of lease liabilities			119900000
	Dividends paid			3493700000
	Interest paid			14100000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-7157100000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-115100000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			-16700000
	Net increase (decrease) in cash and cash equivalents			-131800000
	Cash and cash equivalents cash flow statement at beginning of period			617800000
	Cash and cash equivalents cash flow statement at end of period			486000000